Most Read Articles
4 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
4 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Yesterday
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.

Evidence not strong enough to support routine use of DCBs for STEMI

18 Oct 2020

While drug-coated balloons (DCBs) perform largely comparably to drug-eluting stents (DESs), there is still insufficient evidence to recommend its routine use in patients with ST-elevation myocardial infarction (STEMI), reports a new meta-analysis.

The quantitative analysis included three studies, corresponding to 284 STEMI patients, of whom 138 received DCBs and the remaining 146 were given DESs. Two of the eligible studies were randomized controlled trials (RCT), while the last one was a post-hoc analysis of an RCT.

Target lesion revascularizations occurred more commonly in DCB-treated patients, but not significantly so. The resulting risk estimate was likewise nonsignificant (6.5 percent vs 2.7 percent; odds ratio [OR], 2.51, 95 percent confidence interval [CI], 0.76–8.25; p=0.13).

Similarly, acute thromboses (2.9 percent vs 0 percent; OR, 5.16, 95 percent CI, 0.59–44.97; p=0.14) and major adverse cardiac events (6.5 percent vs 3.4 percent; OR, 1.98, 95 percent CI, 0.69–5.74; p=0.21) were both only nominally elevated in DCB vs DES patients.

The same was also true for myocardial infarctions (1.4 percent vs 1.3 percent; OR, 0.97, 95 percent CI, 0.13–7.29; p=0.98) and all-cause mortality (0.7 percent vs 0 percent; OR, 3.76, 95 percent CI, 0.15–94.83; p=0.42).

On the other hand, type D or worse coronary dissections occurred in a significantly greater frequency in DCB patients (14.5 percent vs 0 percent; OR, 18.4, 95 percent CI, 3.48–93.61; p=0.0006). This contributed to bailout stenting with a bare-metal stent, which also occurred more frequently in DES patients.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
4 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Yesterday
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.